CIC
VIR icon

Cornercap Investment Counsel’s Vir Biotechnology VIR Stock Holding History

Cornercap Investment Counsel’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,587
Closed -$79.3K – 540
2024
Q3 		$79.3K Sell
10,587
-11,937
-53% -$104K 0.02% 493
2024
Q2 		$200K Sell
22,524
-258
-1% -$2.47K 0.03% 539
2024
Q1 		$231K Buy
22,782
+10,320
+83% +$105K 0.04% 550
2023
Q4 		$125K Hold
12,462
– – 0.02% 557
2023
Q3 		$117K Buy
12,462
+2,084
+20% +$29.7K 0.02% 530
2023
Q2 		$255K Hold
10,378
– – 0.04% 478
2023
Q1 		$241K Hold
10,378
– – 0.04% 483
2022
Q4 		$263K Hold
10,378
– – 0.05% 482
2022
Q3 		$200K Buy
+10,378
New +$264K 0.04% 496

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Cornercap Investment Counsel's VIR Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 10,587 shares — an estimated $79.3K sold.

Cornercap Investment Counsel first reported a position in VIR in Q3 2022 and held it in 9 quarters. The position peaked at $263K in Q4 2022. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 10,587 Vir Biotechnology shares in Q4 2024, an estimated $79.3K.
  • Cornercap Investment Counsel first reported a position in Vir Biotechnology in Q3 2022 and held it in 9 quarters.
  • Cornercap Investment Counsel's Vir Biotechnology position peaked at $263K in Q4 2022.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.